Thursday, 07 May 2009 17:56
The dramatic turnaround from lows of a nickel per share ealier this year at cancer biotech Cell Therapeutics (NASDAQ:CTIC) remains on track as the Company announced its 1Q09 results today, which included a 76% reduction of net loss and 301 Moved Permanently expected completion of the pixantrone NDA filing this June. Earlier this week, CTIC announced that pixantrone was made available through a compassionate use program in Europe on a named-patient basis for use in the treatment of aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed or is refractory to standard treatment options.
CTIC achieved its objective thus far during 1H09, including the initiation of the rolling NDA submission for pixantrone, reducing net loss through cost cutting initiatives, raising gross proceeds of $44.3M, and cleaning up the Company's capital structure through the elimination of all previously issued preferred stock. CTIC is on target to complete the pixantrone NDA filing by June and if the FDA grants a priority revew, the Company could receive an approval decision before year-end in December.
|In 2004, European approval for Roche's MabThera marked a major advance in the treatment of indolent non-Hodgkin's lymphoma (NHL), a disease that affects 1.5 million people worldwide. [See Video Below]|
|Animation of MabThera's effect on the human body|
The Company riased $23.8M through the sale of newly-issued preferred stock to a single institutional investor and
301 Moved Permanently the exercise of common stock warrants associated with the transaction. All shares of preferred stock in the deal were subsequently converted into common stock by the investor so that CTIC has no preferred stock outstanding at this time. CTIC received $20.5M in gross proceeds earlier this year from Spectrum Pharma (SPPI) as part of the sale of its 50% stake in their previous joint venture to market cancer drug Zevalin.
CTIC reduced its total net operating expenses by $21.8M to $6.6M for 1Q09, compared to $28.4M in the year-ago period due to the $10.2M one-time gain on the Zevalin joint venture sale along with a decline in R&D spending (down by 50% to $8M versus the year-ago period). Exlcuding the one-time gain, operating expenses still decreased by 41% from the year-ago period. The net loss attributable to common shareholders decreased by 76% or $41.5M to $13.1M or ($0.05) per share, compared to $54.6M or ($7.68) per share in the year-ago period.
Below are links to my previous articles on CTIC at BioMedReports.com:
1.) Cell Therapeutics: Down, but Not Out - 2/20/09
2.) A Resurgence in Cell Therapeutics - 4/2/09
3.) FDA, Clinical Trial Calendar Updates - 4/21/09
4.) FDA Calendar Updates - 5/5/09
Disclosure: No positions.
BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites